ArticlePharmaceuticals (Basel, Switzerland)2021
Use of 3D Printing for the Development of Biodegradable Antiplatelet Materials for Cardiovascular Applications.
Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 48 citations in OpenAlex.
- Reservoir-Type Subcutaneous Implantable Devices Containing Porous Rate Controlling Membranes for Sustained Delivery of Risperidone.Advanced healthcare materials · 2025Article
- 3D-printing of dipyridamole/thermoplastic polyurethane materials for bone regeneration.Drug delivery and translational research · 2025Article
- Evaluation of High-Temperature Sterilization Processes: Their Influence on the Mechanical Integrity of Additively Manufactured Polymeric Biomaterials.Materials (Basel, Switzerland) · 2025Article
- Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment.Drug delivery and translational research · 2025Article
- Investigating Additive Manufacturing Possibilities for an Unmanned Aerial Vehicle with Polymeric Materials.Polymers · 2024Article
- Clopidogrel-loaded vascular grafts prepared using digital light processing 3D printing.Drug delivery and translational research · 2024Article
- Development of 3D-printed vaginal devices containing metronidazole for alternative bacterial vaginosis treatment.International journal of pharmaceutics: X · 2023Article
- A Systematic Analysis of Additive Manufacturing Techniques in the Bioengineering of In Vitro Cardiovascular Models.Annals of biomedical engineering · 2023Review
- Fabrication and Characterisation of 3D-Printed Triamcinolone Acetonide-Loaded Polycaprolactone-Based Ocular Implants.Pharmaceutics · 2023Article
- 3D-printed implantable devices with biodegradable rate-controlling membrane for sustained delivery of hydrophobic drugs.Drug delivery · 2022Article
- Article
- Development of Biodegradable Polymeric Stents for the Treatment of Cardiovascular Diseases.Biomolecules · 2022Review
- A New and Sensitive HPLC-UV Method for Rapid and Simultaneous Quantification of Curcumin and D-Panthenol: Application to In Vitro Release Studies of Wound Dressings.Molecules (Basel, Switzerland) · 2022Article
- Machine Learning and Machine Vision Accelerate 3D Printed Orodispersible Film Development.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Small-diameter synthetic vascular grafts are required for surgical bypass grafting when there is a lack of suitable autologous vessels due to different reasons, such as previous operations. Thrombosis is the main cause of failure of small-diameter synthetic vascular grafts when used for this revascularization technique. Therefore, the development of biodegradable vascular grafts capable of providing a localized and sustained antithrombotic drug release mark a major step forward in the fight against cardiovascular diseases, which are the leading cause of death globally. The present paper describes the use of an extrusion-based 3D printing technology for the production of biodegradable antiplatelet tubular grafts for cardiovascular applications. For this purpose, acetylsalicylic acid (ASA) was chosen as a model molecule due to its antiplatelet activity. Poly(caprolactone) and ASA were combined for the fabrication and characterization of ASA-loaded tubular grafts. Moreover, rifampicin (RIF) was added to the formulation containing the higher ASA loading, as a model molecule that can be used to prevent vascular prosthesis infections. The produced tubular grafts were fully characterized through multiple techniques and the last step was to evaluate their drug release, antiplatelet and antimicrobial activity and cytocompatibility. The results suggested that these materials were capable of providing a sustained ASA release for periods of up to 2 weeks. Tubular grafts containing 10% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.